vestarВестник аритмологииJournal of Arrhythmology1561-86412658-7327НАО «Инкарт»vestar-393Research ArticleОБЗОРЫREVIEWSРОЛЬ ЛАТЕНТНОГО ВОСПАЛЕНИЯ В ПАТОГЕНЕЗЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙROLE OF LATENT INFLAMMATION IN PATHOGENY OF ATRIAL FIBRILLATIONАдамянК. Г.AdamyanK. G.noemail@neicon.ruГригорянС. В.GrigoryanS. V.noemail@neicon.ruАзарапетянЛ. Г.AzarapetyanL. G.noemail@neicon.ruИнститут кардиологии, Национальный институт здравоохранения, Ереван, АрменияRussian Federation20082209202054543441Copyright © Адамян К.Г., Григорян С.В., Азарапетян Л.Г., 20202020Адамян К.Г., Григорян С.В., Азарапетян Л.Г.Adamyan K.G., Grigoryan S.V., Azarapetyan L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestar.elpub.ru/jour/article/view/393

Рассматриваются вопросы участия воспалительных процессов в генезе фибрилляции предсердий, оценивается информативность таких маркеров воспаления как С-реактивный белок, интерлейкин, фактор некроза опухоли в качестве предикторов течения фибрилляции предсердий.

The problem of the role of inflammation in the atrial fibrillation development is considered, the predictive value of inflammation markers including C reactive protein, interleukin, and the tumor necrosis factor for the clinical course of atrial fibrillation is assessed.

фибрилляция предсердийвоспалениемаркеры воспаленияС-реактивный белокинтерлейкинфактор некроза опухолиatrial fibrillationinflammationinflammation markersC reactive proteininterleukintumor necrosis factorReferencesАникин В.В., Калинкин М.Н., Вороная Ю.Л. Показатели иммунной системы у больных с нарушениями ритма сердца //Российский кардиологический журнал, 2001, 3, 22-27.Аникин В.В., Калинкин М.Н., Вороная Ю.Л. Показатели иммунной системы у больных с нарушениями ритма сердца //Российский кардиологический журнал, 2001, 3, 22-27.Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? // «Сердечная недостаточность», 2000, 1, 4, 1-8.Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? // «Сердечная недостаточность», 2000, 1, 4, 1-8.Вахляев В. Д., Недоступ А.В., Царегородцев Д. А., Мазинг М.Ю. Роль гуморальных факторов в патогенезе аритмий сердца // Росс. мед. журнал, 2000, 2, 54-56.Вахляев В. Д., Недоступ А.В., Царегородцев Д. А., Мазинг М.Ю. Роль гуморальных факторов в патогенезе аритмий сердца // Росс. мед. журнал, 2000, 2, 54-56.Волков В.И., Саламех Х.Н., Серик С.А. Про- и противовоспалительные цитокины при сердечной недостаточности В сб: Научные труды Харьк. Гос. мед. института, 2007, 2, 23-28.Волков В.И., Саламех Х.Н., Серик С.А. Про- и противовоспалительные цитокины при сердечной недостаточности В сб: Научные труды Харьк. Гос. мед. института, 2007, 2, 23-28.Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии // Кардиология, 2001, 7, 14-18.Гуревич М.А. Практические аспекты этиологии, систематизации и лечения мерцательной аритмии // Кардиология, 2001, 7, 14-18.Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Предикторы внутрисердечного тромбоза у больных с мерцательной аритмей : факторы гемостаза, маркеры воспаления и генетические факторы // Кардиология, 2007, 11, 46-54.Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Предикторы внутрисердечного тромбоза у больных с мерцательной аритмей : факторы гемостаза, маркеры воспаления и генетические факторы // Кардиология, 2007, 11, 46-54.Клиническая иммунология. / Под ред. Караулов А.В.- М., 1999, 600 с.Клиническая иммунология. / Под ред. Караулов А.В.- М., 1999, 600 с.Кушаковский М. С. Аритмии сердца. Руководство для врачей, СПб.: ИКФ «Фолиант»» 2004, 672 с.Кушаковский М. С. Аритмии сердца. Руководство для врачей, СПб.: ИКФ «Фолиант»» 2004, 672 с.Литвицкий П.Ф., Войнов В.А. Патофизиология. Часть 1. М., 1992, с. 60-72.Литвицкий П.Ф., Войнов В.А. Патофизиология. Часть 1. М., 1992, с. 60-72.Насонов Е.Л. Современные иммунологические концепции в кардиологии // Тер. арх. 1986, 10, 7-14.Насонов Е.Л. Современные иммунологические концепции в кардиологии // Тер. арх. 1986, 10, 7-14.Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка // Кардиология, 1992, 2, 81-85.Насонов Е.Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка // Кардиология, 1992, 2, 81-85.Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные) // Кардиология, 2002, 7, 53-62.Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные) // Кардиология, 2002, 7, 53-62.Насонов Е.Л., Самсонов М.Ю, Беленков Ю.Н. Иммунопатология застойной сердечной недостаточности: роль цитокинов // Кардиология, 1999, 3, 66-73.Насонов Е.Л., Самсонов М.Ю, Беленков Ю.Н. Иммунопатология застойной сердечной недостаточности: роль цитокинов // Кардиология, 1999, 3, 66-73.Насонов Е.Л., Самсонов М.Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли // Мед. русс. журнал, 2000, 1, 4, 22-36.Насонов Е.Л., Самсонов М.Ю. Новые аспекты патогенеза сердечной недостаточности: роль фактора некроза опухоли // Мед. русс. журнал, 2000, 1, 4, 22-36.Озова Е.М., Киякбаев Г.К., Кабалава Ж.Д. Воспаление и хроническая сердечная недостаточность. Роль статинов // Кардиология, 2007, 1, 52-62.Озова Е.М., Киякбаев Г.К., Кабалава Ж.Д. Воспаление и хроническая сердечная недостаточность. Роль статинов // Кардиология, 2007, 1, 52-62.Ольбинская Л.И., Игнатенко С.Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью // Сердечная недостаточность, 2001, 2, 3, 33-39.Ольбинская Л.И., Игнатенко С.Б. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью // Сердечная недостаточность, 2001, 2, 3, 33-39.Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий // Врач, 2007, 1 (16), 49-53.Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий // Врач, 2007, 1 (16), 49-53.Тарасова О.А. С-реактивный протеин и фактор некроза опухолей-альфа при фибрилляции предсердий у пациентов с артериальной гипертонией, их прогностическая значимость // Сибирский медицинский журнал, Томск, 2007, 1(22), 29-34.Тарасова О.А. С-реактивный протеин и фактор некроза опухолей-альфа при фибрилляции предсердий у пациентов с артериальной гипертонией, их прогностическая значимость // Сибирский медицинский журнал, Томск, 2007, 1(22), 29-34.Тарасова О.А. СРП и ФНО-альфа при фибрилляции предсердий // Актуальные вопросы клинической медицины, Пермь, 2005, 146-150.Тарасова О.А. СРП и ФНО-альфа при фибрилляции предсердий // Актуальные вопросы клинической медицины, Пермь, 2005, 146-150.Фрейдлин И.С. Цитокины и межклеточные контакты в противоинфекционной защите организма В Сб: Труды С-Пб мед. университета 2007, 3, 21-27.Фрейдлин И.С. Цитокины и межклеточные контакты в противоинфекционной защите организма В Сб: Труды С-Пб мед. университета 2007, 3, 21-27.Abdelhadi R.H.,Chung M.K.,Wagoner D.R. New hope for the prevention of recurrent atrial fibrillation // Circulation, 1997, 96, 3542-3548.Abdelhadi R.H.,Chung M.K.,Wagoner D.R. New hope for the prevention of recurrent atrial fibrillation // Circulation, 1997, 96, 3542-3548.Acevedo M. et al. C-reacrive protein and atrial fibrillation: evidence for the presence of inflammation in the perpetuation of the arrhythmia // Int. J Cardiolog. 2006, 14, 108 (3), 326-331.Acevedo M. et al. C-reacrive protein and atrial fibrillation: evidence for the presence of inflammation in the perpetuation of the arrhythmia // Int. J Cardiolog. 2006, 14, 108 (3), 326-331.Agmon Y., Khandheria B., Meissner I. et al. Serum C-reactive protein levels are associated with the presence and severity of atherosclerosis of the thoracic aorta; a population-based transesophageal echocardiographic study // Circulation 2000, 102, II, 43.Agmon Y., Khandheria B., Meissner I. et al. Serum C-reactive protein levels are associated with the presence and severity of atherosclerosis of the thoracic aorta; a population-based transesophageal echocardiographic study // Circulation 2000, 102, II, 43.AndersonJ.L., Maycock C.A., Lappe D. Frequency of elevation of C-reactive protein in atrial fibrillation // Am. J. Cardiol. 2004, 94, 1255-1259.AndersonJ.L., Maycock C.A., Lappe D. Frequency of elevation of C-reactive protein in atrial fibrillation // Am. J. Cardiol. 2004, 94, 1255-1259.Aviles R.J., Martin D.O., Apperson-Hansen C. et all. Infiammation as a rick factor for atrial fibrillation // Circulation 2003, 108 (24), 3006-3010.Aviles R.J., Martin D.O., Apperson-Hansen C. et all. Infiammation as a rick factor for atrial fibrillation // Circulation 2003, 108 (24), 3006-3010.Azzawi M., Hasleton P. Tumor necrosis factor alpha and cardiovascular system: its role in cardiac allograft and heart disease // Cardiovasc. Res. 1999, 850-859.Azzawi M., Hasleton P. Tumor necrosis factor alpha and cardiovascular system: its role in cardiac allograft and heart disease // Cardiovasc. Res. 1999, 850-859.Bataile R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo // Arthritis Rheum 1992, 35, 982-984.Bataile R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo // Arthritis Rheum 1992, 35, 982-984.Bazzоni F., Beutier B. Tumor necrosis factor ligant and receptor families // N. Engl. J. Med. 1996, 334, 1717-1725.Bazzоni F., Beutier B. Tumor necrosis factor ligant and receptor families // N. Engl. J. Med. 1996, 334, 1717-1725.Biasucci L., Liuzzo G., Grillo R.L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation 1999, 99, 855-860.Biasucci L., Liuzzo G., Grillo R.L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation 1999, 99, 855-860.Biasucci L.M., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina // Circulation, 1996, 94, 5, 874-877.Biasucci L.M., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina // Circulation, 1996, 94, 5, 874-877.Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease; application to clinical and public health practice; clinical use of inflammatory markers in patients with cardiovascular diseases; a background paper // Circulation 2004, 110, 560-567.Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease; application to clinical and public health practice; clinical use of inflammatory markers in patients with cardiovascular diseases; a background paper // Circulation 2004, 110, 560-567.Boss Ch.J, Anderson R.A. Lip G.Y.H. Is atrial fibrillation an inflammatory disorders? // Eur. Heart J. 2006, 27, 136-149.Boss Ch.J, Anderson R.A. Lip G.Y.H. Is atrial fibrillation an inflammatory disorders? // Eur. Heart J. 2006, 27, 136-149.Boss Ch.J, Lip G.Y.H. Targeting the renin-angiotensin -aldosterone system in atrial fibrillation: from pathology to clinical trials // J. Hum. Hypertens, 2005, 19, 855-859.Boss Ch.J, Lip G.Y.H. Targeting the renin-angiotensin -aldosterone system in atrial fibrillation: from pathology to clinical trials // J. Hum. Hypertens, 2005, 19, 855-859.Boss Ch.J., Lip G.YH. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers // J. Am. Coll Cardiol 2006, 47, 889-890.Boss Ch.J., Lip G.YH. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers // J. Am. Coll Cardiol 2006, 47, 889-890.Bozkurt B., Kribbs S.B., Clubb F.J. et all. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats // Circulation 1998, 97, 1382-1391.Bozkurt B., Kribbs S.B., Clubb F.J. et all. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats // Circulation 1998, 97, 1382-1391.Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis // J Am Coll Cardiol 1998, 32(7), 2057-2064.Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis // J Am Coll Cardiol 1998, 32(7), 2057-2064.Cheruku K.K., Ghani A., Ahmad F. et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery // Prev Cardiol, 2004, 7, 13-18.Cheruku K.K., Ghani A., Ahmad F. et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary bypass graft surgery // Prev Cardiol, 2004, 7, 13-18.Chloe A. et al. Is atrial fibrillation an inflammatory disease reflected be elevation C-reactive protein? // Suppl to J. of the American College of Cardiology 2003, March, l 41, 6, Suppl. A absrt 1089-17/Chloe A. et al. Is atrial fibrillation an inflammatory disease reflected be elevation C-reactive protein? // Suppl to J. of the American College of Cardiology 2003, March, l 41, 6, Suppl. A absrt 1089-17/Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation // Circulation 2001, 104, 2886-2891.Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation // Circulation 2001, 104, 2886-2891.Conway D.S.G. et al. Relationship of Interkeukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation // J. of the American College of Cardiology, 2003.Conway D.S.G. et al. Relationship of Interkeukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation // J. of the American College of Cardiology, 2003.Corrado E, Rizzo M, Tantillo R, et all. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study // Stroke 2006, 37, 482-486.Corrado E, Rizzo M, Tantillo R, et all. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study // Stroke 2006, 37, 482-486.Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses // BMJ 2000, 22, 321 (7255), 199-204.Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses // BMJ 2000, 22, 321 (7255), 199-204.Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation // Amer. Heart J, 2005, 12-14.Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation // Amer. Heart J, 2005, 12-14.Dernellis J., Panareotou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implicftion of an inflammatory process in paroxysmal atrial fibrillation // Acta Cardiol, 2001, 56, 375-380.Dernellis J., Panareotou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implicftion of an inflammatory process in paroxysmal atrial fibrillation // Acta Cardiol, 2001, 56, 375-380.Dernellis J., Panareotou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation // Eur. Heart J, 2004, 25, 1100-1107.Dernellis J., Panareotou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation // Eur. Heart J, 2004, 25, 1100-1107.Ellinor P.T. et al. C-reactive protein in lone atrial fibrillation // Am J Cardiol 2006, 1, 98 (7), 991-992.Ellinor P.T. et al. C-reactive protein in lone atrial fibrillation // Am J Cardiol 2006, 1, 98 (7), 991-992.Engelmann M.D., Ogard C.G., Niemann L et al. Increased levels of multiple markers of inflammation in patients with persistent atrial fibrillation // Scan. Cardiovasc. J. 2005, 39, 36.Engelmann M.D., Ogard C.G., Niemann L et al. Increased levels of multiple markers of inflammation in patients with persistent atrial fibrillation // Scan. Cardiovasc. J. 2005, 39, 36.Engelmann M.D., Svedsen J.H The emerging role of inflammation in atrial fibrillation and the potential of antiinflammatory intervention: reply // Eur.Heart J., 2005, 26 (20), 2208-2209.Engelmann M.D., Svedsen J.H The emerging role of inflammation in atrial fibrillation and the potential of antiinflammatory intervention: reply // Eur.Heart J., 2005, 26 (20), 2208-2209.Engelmann M.D.M., Svedsen J.H. Inflammation in the genesis of atrial fibrillation // Eur. Heart J. 2005, 20(26), 2083-2092.Engelmann M.D.M., Svedsen J.H. Inflammation in the genesis of atrial fibrillation // Eur. Heart J. 2005, 20(26), 2083-2092.Falk R.H. Atrial Fibrillation // NEJM 2001, 344, 14, 1067-1078.Falk R.H. Atrial Fibrillation // NEJM 2001, 344, 14, 1067-1078.Ford E.S., Giles W.H. Serum C-reactive protein and self- reported stroke. Findings from the Third National Health and Nutrition Examination Survey // Arteriocler Thromb Vasс Biol 2000; 20: 1052-1056.Ford E.S., Giles W.H. Serum C-reactive protein and self- reported stroke. Findings from the Third National Health and Nutrition Examination Survey // Arteriocler Thromb Vasс Biol 2000; 20: 1052-1056.Gabay C., Kushnewer I. Acute-phase proteins and other systemic responses to inflammation // N Engl J Med 1999, 340, 448-454.Gabay C., Kushnewer I. Acute-phase proteins and other systemic responses to inflammation // N Engl J Med 1999, 340, 448-454.Haverkate F., Thompson S.G., Pyke S.D.M. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina // Lancet 1997, 349, 462-466.Haverkate F., Thompson S.G., Pyke S.D.M. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina // Lancet 1997, 349, 462-466.Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target // Rev. Esp. Cardiol. 2006, 59, 94-98.Hernandez A. C-reactive protein and atrial fibrillation. An old marker looking for new target // Rev. Esp. Cardiol. 2006, 59, 94-98.Issac T.T., Dokanish H., Lakkis N.M. Amer. J. Cardiol. 2007, 11, 443-445Issac T.T., Dokanish H., Lakkis N.M. Amer. J. Cardiol. 2007, 11, 443-445Kallergis E.M. et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation // Heart rhythm disorders and pacemakers, 2007, 2, 443-446.Kallergis E.M. et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation // Heart rhythm disorders and pacemakers, 2007, 2, 443-446.Koening W., Sund M., Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992 // Circulation 1999, 99, 237-242.Koening W., Sund M., Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992 // Circulation 1999, 99, 237-242.Lagrand W.K., Visser C.A., Hermens W.T et al. C- reactive protein as cardiovascular risk factor: more than an epiphenomenona // Circulation 1999, 1000, 96-102.Lagrand W.K., Visser C.A., Hermens W.T et al. C- reactive protein as cardiovascular risk factor: more than an epiphenomenona // Circulation 1999, 1000, 96-102.Lee KWJ, Hill JS, Walley KR et al. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort // CMAJ 2006, 174, 461-466.Lee KWJ, Hill JS, Walley KR et al. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort // CMAJ 2006, 174, 461-466.Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease // N Engl J Med 2000, 343 (16), 1139-1147.Lindahl B, Toss H, Siegbahn A et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease // N Engl J Med 2000, 343 (16), 1139-1147.Loricchio M.L., Cianfrocca C., Pasceri V et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardiovertion // Am. J. Cardiol. 2007, 99, 1421-1424.Loricchio M.L., Cianfrocca C., Pasceri V et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardiovertion // Am. J. Cardiol. 2007, 99, 1421-1424.Mann D.J., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines // Chest 1994, 105, 897-904.Mann D.J., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines // Chest 1994, 105, 897-904.Martins TB, Anderson JL, Muhlestein JB et all. Risk factor analysis of plasma cytokines in patient with coronary artery disease by a multiplexed fluorescent immunoassay // Am J Clin Pathol 2006, 125, 906-913.Martins TB, Anderson JL, Muhlestein JB et all. Risk factor analysis of plasma cytokines in patient with coronary artery disease by a multiplexed fluorescent immunoassay // Am J Clin Pathol 2006, 125, 906-913.Mendall M.A., Strachman D.P., Butland B.K. et al. C-reactive protein: relation to total mortality, cardiovascular risk factors in man // Eur Heart J 2000, 21,1584-1590.Mendall M.A., Strachman D.P., Butland B.K. et al. C-reactive protein: relation to total mortality, cardiovascular risk factors in man // Eur Heart J 2000, 21,1584-1590.Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease // Circulation, 2000, 102, 1755-1760.Muhlestein JB, Anderson JL, Carlquist JF et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease // Circulation, 2000, 102, 1755-1760.Muller-Werdan U, Werdan K. Immune modulation by catecholamines - a potential mechanism of cytokine release in Heart failure // Herz 2000, 25, 3, 1838-1842.Muller-Werdan U, Werdan K. Immune modulation by catecholamines - a potential mechanism of cytokine release in Heart failure // Herz 2000, 25, 3, 1838-1842.Nissen S.E ,Tuzcu E.M.,Schoenhagen P et a.l Effect of intensive compared with moderate lipid-loowering therapy on progression of coronary athresclerosis: a randomized controlled trial // JAMA, 2004, 291, 1071-1080.Nissen S.E ,Tuzcu E.M.,Schoenhagen P et a.l Effect of intensive compared with moderate lipid-loowering therapy on progression of coronary athresclerosis: a randomized controlled trial // JAMA, 2004, 291, 1071-1080.Ockene L.S., Mathews C.D., Rifai N. et all. Validity and classification accuracy of serial nigh-sensitive C-reac tive protein measurements in healthy adults // Clin Chem 2001, 47, 444-450.Ockene L.S., Mathews C.D., Rifai N. et all. Validity and classification accuracy of serial nigh-sensitive C-reac tive protein measurements in healthy adults // Clin Chem 2001, 47, 444-450.Pearson TA, Mensah GA, Alexander RW et all. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association // Circulation 2003, 107, 499-551.Pearson TA, Mensah GA, Alexander RW et all. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association // Circulation 2003, 107, 499-551.Pepys M.B, Hirschfield G.M. C-reactive protein: a critical update // J.Clin. Invest 2003, 111, 1805-1812.Pepys M.B, Hirschfield G.M. C-reactive protein: a critical update // J.Clin. Invest 2003, 111, 1805-1812.Psichary S.N. et al. Relation of elevated C-reactive protein and IL-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation // Am.J.Cardiol. 2005, 95, 764-767.Psichary S.N. et al. Relation of elevated C-reactive protein and IL-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation // Am.J.Cardiol. 2005, 95, 764-767.Rader D. J. Inflammatory markers of coronary risk // N Engl J Med 2000, 343, 1179-1182.Rader D. J. Inflammatory markers of coronary risk // N Engl J Med 2000, 343, 1179-1182.Rauchhaus M et all Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure // J. Am. Coll. Cardiol. 2003, 42, 1933-1940.Rauchhaus M et all Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure // J. Am. Coll. Cardiol. 2003, 42, 1933-1940.Rauchhaus M, Doeher W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure // Circulation 2000, 102, 3060-3067.Rauchhaus M, Doeher W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure // Circulation 2000, 102, 3060-3067.Ridker P., Hennekens C., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // N Engl J Med 2000, 836-843.Ridker P., Hennekens C., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women // N Engl J Med 2000, 836-843.Ridker P.M. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease // Circulation 2001, 103, 1813-1821.Ridker P.M. High-sensitive C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease // Circulation 2001, 103, 1813-1821.Ridker P.M., Buring J. E., Shin J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparentiy healthy women // Circulation 1998, 98, 731-733.Ridker P.M., Buring J. E., Shin J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparentiy healthy women // Circulation 1998, 98, 731-733.Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men // N Engl J Med 1997, 336, 973-979.Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men // N Engl J Med 1997, 336, 973-979.Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction // Circulation, 1998, 97, 2007-2011.Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction // Circulation, 1998, 97, 2007-2011.Ridker PM, Rifai N. Pfeffer MA et all. Inflammation, Pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels // Circulation 1998, 98, 839-844.Ridker PM, Rifai N. Pfeffer MA et all. Inflammation, Pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels // Circulation 1998, 98, 839-844.Rifai N., Tracy R. P., Ridker P. M. Clinical efficacy ofan automated highsensitivity C-reactive protein assay // Clin Chem 1999; 45: 2136-2141.Rifai N., Tracy R. P., Ridker P. M. Clinical efficacy ofan automated highsensitivity C-reactive protein assay // Clin Chem 1999; 45: 2136-2141.Roberts W.L., Moulton L., Law T. C. et al. Evaluation of nine automated high sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 47, 418-423.Roberts W.L., Moulton L., Law T. C. et al. Evaluation of nine automated high sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 47, 418-423.Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automated high-sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 46, 461-468.Roberts W.L., Sedrick R., Moulton L. et al. Evaluation of four automated high-sensitive C-reactive protein methods; implications for clinical and epidemiological applications // Clin Chem 2000, 46, 461-468.Roivanen M., Viik-Kajander M., Palouso T. et al. Infections, inflammation, and the risk of coronary heart disease // Circulation 2000, 10, 252-257.Roivanen M., Viik-Kajander M., Palouso T. et al. Infections, inflammation, and the risk of coronary heart disease // Circulation 2000, 10, 252-257.Sanchez P.L. et al. Do baseline C-reactive protein lev els predict the new - onset of atrial fibrillation in hftients with acute coronary syndrome? // Europ. Heart J. 2003. Suppl August - September 24, abstr 509.Sanchez P.L. et al. Do baseline C-reactive protein lev els predict the new - onset of atrial fibrillation in hftients with acute coronary syndrome? // Europ. Heart J. 2003. Suppl August - September 24, abstr 509.Sata N., Hamada N. et al. C-Reactive Protein and atrial fibrillation. Is inflamation a conssequence or a cause of atrial fibrillation? // Jpn Heart J 2004, 45, 3, 441-445.Sata N., Hamada N. et al. C-Reactive Protein and atrial fibrillation. Is inflamation a conssequence or a cause of atrial fibrillation? // Jpn Heart J 2004, 45, 3, 441-445.Schonbek U, Libby P. Inflammation, Immunity, and HMG-CjA Reductase Inhibitors: Statins as Antiinflammatory Agents? // Ciculation 2004, 109, 18-26.Schonbek U, Libby P. Inflammation, Immunity, and HMG-CjA Reductase Inhibitors: Statins as Antiinflammatory Agents? // Ciculation 2004, 109, 18-26.Serrano C.V., Ramires J.A.F., Venturinelli M. et al. Coronary angioplasty results in leukocytes and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty // J Am Coll Cardiol 1997, 29, 1276-1283.Serrano C.V., Ramires J.A.F., Venturinelli M. et al. Coronary angioplasty results in leukocytes and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty // J Am Coll Cardiol 1997, 29, 1276-1283.Sideris A.N., Letsas K. Inflammation and Atrial Fibrillation // Hospital Chronicles 2006, Suppl. 128-134.Sideris A.N., Letsas K. Inflammation and Atrial Fibrillation // Hospital Chronicles 2006, Suppl. 128-134.Steel D.M., Alexander A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid protein A. // Immunol Today 1994, 74, 80-87.Steel D.M., Alexander A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid protein A. // Immunol Today 1994, 74, 80-87.Stranberg T.E., Tilvis R.S. C-reactive protein. Cardiovascular risk factors, and mortality in the prospective study in the elderly // Arterioscl. Thromb. Vasc. Biol 2000, 20, 1057-1060.Stranberg T.E., Tilvis R.S. C-reactive protein. Cardiovascular risk factors, and mortality in the prospective study in the elderly // Arterioscl. Thromb. Vasc. Biol 2000, 20, 1057-1060.Szodoray P, Timar O, et all. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease // Scand J Immunol 2006, 64, 336-344.Szodoray P, Timar O, et all. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease // Scand J Immunol 2006, 64, 336-344.Toss H., Lindahl B., Siegbahn A. et al. For the FRISC Study Group. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease // Circulation 1997, 96, 4204-4210.Toss H., Lindahl B., Siegbahn A. et al. For the FRISC Study Group. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease // Circulation 1997, 96, 4204-4210.Tracy R.P. Inflammation in cardiovascular disease. Cart, Horse, or Both. // Circulation 1998, 97, 2000-2002.Tracy R.P. Inflammation in cardiovascular disease. Cart, Horse, or Both. // Circulation 1998, 97, 2000-2002.Tracy R.P. Inflammation markers and coronary heart disease. // Curr Opin Lipidol 1999, 10, 435-441.Tracy R.P. Inflammation markers and coronary heart disease. // Curr Opin Lipidol 1999, 10, 435-441.Vanderheyden M, Kersschot E, Paulus W. Pro-inflammatory cytokines and endothelium-depent vasodilatation in the forearm // Eur.Heart J. 1998, 19, 747-752.Vanderheyden M, Kersschot E, Paulus W. Pro-inflammatory cytokines and endothelium-depent vasodilatation in the forearm // Eur.Heart J. 1998, 19, 747-752.Vigushi D.M., Pepys M., Hawkins P.N. Metabolic and scintigraphic studies of radiodinated human C-reactive protein in health and disease // J Clin Invest 1993, 91, 1351-1357.Vigushi D.M., Pepys M., Hawkins P.N. Metabolic and scintigraphic studies of radiodinated human C-reactive protein in health and disease // J Clin Invest 1993, 91, 1351-1357.Watanabe T., Takeishi Y., Hirono O. et al. C-reactive protein elevation predicts the occurrence of atrial structual remodeling in patients with paroxysmal atrial fibrillation // Heart Vessels 2005, 20, 2, 45-49.Watanabe T., Takeishi Y., Hirono O. et al. C-reactive protein elevation predicts the occurrence of atrial structual remodeling in patients with paroxysmal atrial fibrillation // Heart Vessels 2005, 20, 2, 45-49.Wazni O., Martin D.O., Marrouche N.F. et al. Creacrive protein concentration and reccurence of atrial fibrillation after electrical cardioversion // Heart 2005, 91, 1303-1305.Wazni O., Martin D.O., Marrouche N.F. et al. Creacrive protein concentration and reccurence of atrial fibrillation after electrical cardioversion // Heart 2005, 91, 1303-1305.Wei C.M., Lerman A., Rodeheffer R.J. et al. Endothelin in human congestive heart failure // Circulation 1994, 89, 1580-1586.Wei C.M., Lerman A., Rodeheffer R.J. et al. Endothelin in human congestive heart failure // Circulation 1994, 89, 1580-1586.Woods A., Brull D. J., Humphries S. E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 // Eur Heart J 2000, 21, 1574-1583.Woods A., Brull D. J., Humphries S. E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 // Eur Heart J 2000, 21, 1574-1583.Zhang M., Tracey K.L. Tumor necrosis factor. In : Thompson A.W. The cytokine handbook? 3-rd ed. New York, Academic press, 1998, 515-548.Zhang M., Tracey K.L. Tumor necrosis factor. In : Thompson A.W. The cytokine handbook? 3-rd ed. New York, Academic press, 1998, 515-548.

The authors declare that there are no conflicts of interest present.